Meda Expands Collaboration With Etypharm

Meda has reported that it has expanded its collaboration with the French development company, Etypharm for the patented product, Axorid. The company said that new territories such as East Europe with Russia and Turkey, are included in the collaboration. Previously, the company held commercialization rights in Central and West Europe.

The company claims that Axorid consists of well-known and broadly used substances; ketoprofen, a Non Sterodial Anti-Inflammatory Drug for the treatment of rheumatic disorders, and omeprazole, an acid reducing proton pump inhibitor (PPI).

Axorid can prevent gastrointestinal side effects from use of Non Sterodial Anti-Inflammatory Drugs. Axorid’s once-daily administration can also increase patient compliance.

Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in more than 40 countries.